Immunomedics Appoints Special Advisor to Its Chairman

Immunomedics, Inc.  today announced that Dr. Sol J. Barer has been appointed special advisor to the chairman, and will work in this capacity to strengthen the Company’s business and commercial development activities.

Barer is managing partner of SJ Barer Consulting. From 1987 to 2011, he served in various senior management roles at Celgene Corporation, including executive chairman, chairman and CEO, and president and COO. Prior thereto, he was a founder of the biotechnology group at Celanese Corporation, which then became Celgene.

Barer serves on the Board of Directors of Teva Pharmaceutical Industries, Contrafect, Amicus Therapeutics, and Aegerion Pharmaceuticals, in addition to four other healthcare companies. He received a Ph.D. in organic and physical chemistry from Rutgers University, and a B.S. in chemistry from Brooklyn College of the City of New York.

David M. Goldenberg, chairman and Founder of Immunomedics, commented: “The Board of Directors and I are delighted and honored to have such a successful and seasoned biopharmaceutical executive join our team. This is a pivotal time for the Company as we advance our lead antibody-drug conjugate, sacituzumab govitecan, in partnering efforts towards eventual commercialization in the therapy of patients with triple-negative breast cancer as well as other major cancer types.” “We look forward to Barer playing an important role in the Company’s developments,” Goldenberg added.

Barer remarked: “I have observed Immunomedics for many years, since Celgene and Immunomedics both were neighbors in Warren. I admire the diverse and innovative scientific platforms being developed, and look forward to assisting in strategic development and commercialization of their novel antibody-drug conjugates, as well as immuno-oncology products in early development.” “It is critical to bring these and other compounds in development to the benefit of cancer patients as soon as possible,” Dr. Barer commented further.

Related Articles: